Assembly Biosciences (ASMB) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.93

Estimate

-$0.49

Surprise

-88.0%

Revenue (period 2026-09-30)

$3.0M

Score today

5.1/10

Revenue source: xbrl.

Assembly Biosciences (ASMB) reported a wider loss than forecast — adjusted EPS of -$0.93 against the -$0.49 estimate (a 88.0% shortfall).

• Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates — fiscal.ai, 2026-11-12
• Assembly Biosciences Q3 EPS $(0.93) Misses $(0.46) Estimate, Sales $2.956M Miss $7.259M Estimate — benzinga, 2026-11-12
• H.C. Wainwright Maintains Buy Rating on Assembly Biosciences — fiscal.ai, 2026-11-11

TrendMatrix currently rates ASMB Sell at 5.1/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate; this quarter's -88.0% surprise compares with a +97.6% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$21.12

Price target

$44.54

Stop

$19.64

Upside to target

+110.9%

Reward-to-risk

9.2:1

Model outputs from TrendMatrix’s engine as of 2026-11-15 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$432.5M

P/E (fwd)

-8.2

P/E (ttm)

28.2

52-week range

$19.20–$39.71

Off 52-week high

46.8%

RSI (14)

58

Volume vs avg

1.31×

Score today

5.1/10